BioNTech, Pfizer ask Europe to OK vaccine for emergency use

BioNTech said that if the vaccine, currently named BNT162b2, is approved, its use in Europe could begin before the end of 2020.

Published: 01st December 2020 04:21 PM  |   Last Updated: 01st December 2020 04:21 PM   |  A+A-

Pfizer vaccine

The first patient enrolled in Pfizer's COVID-19 coronavirus vaccine clinical trial at the University of Maryland School of Medicine in Baltimore. (Photo | AP)

By PTI

BERLIN: German pharmaceutical company BioNTech and its US partner Pfizer say they have submitted an application for conditional approval of their coronavirus vaccine with the European Medicines Agency.

The two companies said on Tuesday that the submission, which occurred Monday, completes the rolling review process they initiated with the agency on October 6.

The move comes a day after rival Moderna said it was asking US and European regulators to allow emergency use of its COVID-19 vaccine.

BioNTech said that if the vaccine, currently named BNT162b2, is approved, its use in Europe could begin before the end of 2020.


Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.